60 Binney St
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
421 articles with bluebird bio
As May gets off to a slow start for the FDA calendar, a few companies have important target action dates.
Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy's cost-effectiveness.
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
Following a review of its strategic priorities, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is initiating a comprehensive restructuring intended to deliver up to $160 million in cost savings over the next two years.
Following the ongoing trend in the pharmaceutical industry, approximately 30% of bluebird’s staff will be let go in an effort to reduce operational costs to under $340 million by the end of 2022.
Shares of bluebird bio were falling rapidly in premarket trading Monday morning after the company revealed its dire financial straits over the weekend.
bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021, shared recent operational progress, and provided a corporate update.
Recent gene therapy research has created a durable response in terms of producing normally-shaped red blood cells and reducing the pain of sickle cell disease.
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD).
The extensions are due to the FDA's requiring more time to review additional clinical data it had requested from bluebird.
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.
The FDA placed bluebird bio's clinical trial for its candidate sickle cell disease (SCD) treatment on partial hold for participants under 18 years old.
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
bluebird bio, Inc . (NASDAQ: BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD) on partial clinical hold for patients under the age of 18.
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for elivaldogene autotemcel (eli-cel, Lenti-D®), the company’s gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process.
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week's ARASENS trial results should help pave the road.
The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).